ClinicalTrials.gg
RecruitingNCT06691750CESARISUpdated Nov 3, 2026

Clinical Impact of Uterine Repair During Cesarean Section With Barbed Suture on the Incidence of Isthmocele

An interventional study of Barbed suture and Conventional smooth suture in Isthmocele, Cesarean Scar Defect and Pelvic Pain, sponsored by Hospital Clinic of Barcelona. Recruiting at 1 site in Spain. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Hospital Clinic of Barcelona · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.
Updated Nov 3, 2026Primary completion movedEnrollment updated+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Pelvic Pain with a site in Spain — 6 open to participants now, 6 under way, none of them phase 3. Pelvic Pain · Spain.

Planned enrollment
3rd of 22
420 · median 69
Started
2024
with 1 other
No phase
16 of 27
5 open now
Registered
20th of 27
by date
Lead sponsor
2 of 27
Hospital Clinic of Barcelona

Among the 27 studies in Pelvic Pain with a site in Spain, this one is the 3rd largest by planned enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2024, is one of 16 with no phase, and was the 20th registered.

Pelvic Pain

377 studies on the registry are indexed under Pelvic Pain; 91 are open to participants now.

Browse Pelvic Pain studies →

Open to participants now

6 of the 27 studies in Pelvic Pain with a site in Spain are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 61 Pelvic Pain studies recruiting now, 22 (36%) set no upper age limit and 37 (61%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Pelvic Pain with a site in Spain, or all of them as a file.
02

Study summary

Pregnant women, irrespective of their pregnancy risk, who undergo a cesarean section for any reason will be randomized to one of two suturing techniques: conventional suture or barbed suture for uterine repair after the cesarean section. Following surgery, these patients will be followed up for clinical outcomes, ultrasound evaluation of the uterine scar, and study of the hypoxic-inflammatory environment of the uterine cavity.

Read the detailed description

A randomized controlled trial will be conducted among pregnant women, irrespective of their pregnancy risk, undergoing cesarean sections at a tertiary care hospital. Participants will be randomly assigned to one of two groups: the intervention group, which will receive barbed suture for myometrial repair following the cesarean section, or the control group, which will receive conventional smooth suture. This study aims to compare a range of outcomes related to clinical, ultrasonographic, and molecular parameters of the uterine scar and the development of isthmocele.

Main hypothesis: The use of barbed suture for hysterorrhaphy during cesarean section, compared to conventional smooth sutures, results in reduced ischemia and necrosis of the myometrial tissue, facilitating better healing. This is associated with a lower incidence of isthmocele at six months postpartum, and a decrease in its ultrasound dimensions, evaluated by transvaginal ultrasound with hysterosonography.

Secondary hypothesis:

  • The use of barbed suture during cesarean delivery leads to a reduction in molecular biomarker levels of hypoxia and inflammation within the uterine cavity.
  • The employment of barbed suture is associated with a decrease in the frequency of symptoms related to isthmocele in the short term, or a lower intensity of symptoms if they occur, compared to conventional suture.
  • Patients who develop isthmocele after cesarean delivery present predisposing myometrial characteristics and additional risk factors compared to patients with normal healing.
  • The study of myometrial texture patterns based on ultrasound images of the uterine wall in the postpartum period following cesarean delivery may provide predictive data regarding the risk of developing isthmocele at six months postpartum.
  • The stiffness of the uterine scar measured by the strain ratio (SR) is lower among patients included in the barbed suture group than in patients in the conventional suture group.
  • Uterine repair with barbed suture during the cesarean section leads to better perinatal outcomes in the subsequent pregnancies.
03

Conditions studied

  • Isthmocele
  • Cesarean Scar Defect
  • Pelvic Pain
  • Spotting
  • Infertility
  • Uterine Niche
  • Uterine Abnormal Bleeding
  • Niche

Keywords

  • Isthmocele
  • Uterine niche
  • Cesarean scar defect
  • Barbed suture
  • Cesarean section
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women who deliver at Hospital Clinic of Barcelona by a planned, intrapartum or urgent cesarean section, irrespective of their pregnancy risk.
  • Had accepted to participate in the study during the third trimester of gestation.
  • Patients who accept a 6-month follow-up visit.
  • Minimal maternal age of 18 years old.

Exclusion criteria

Exclusion Criteria:

  • Patients who end up delivering in another center.
  • Patients who deliver by vaginal route.
  • Patients diagnosed with isthmocele prior to the current pregnancy.
  • Need for histerectomy in the following 6 months after delivery.
  • Patients with known allergies to any of the components of the barbed suture.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
420 participants (estimated)

Study arms

  • Experimental
    Study Group: Uterine repair with barbed suture

    Uterine closure following cesarean section is carried out using an unlocked single-layer barbed suture with an endometrium-free technique.

    Device: Barbed suture

  • Active comparator
    Control Group: Uterine repair with conventional smooth suture

    Uterine repair following cesarean section is performed using a conventional smooth polyglactin suture with a continuous single-layer, endometrium-free technique, in accordance with the standard procedure at our center.

    Device: Conventional smooth suture

Interventions

  • DeviceBarbed suture

    Size 0 barbed absorbable monofilament suture with unidirectional spikes that includes a loop in one of its ends, not requiring knots.

  • DeviceConventional smooth suture

    Size 1 smooth multifilament absorbable polyglactin suture.

06

What researchers measure

Primary outcomes

  1. Rate of Isthmocele

    Rate of isthmocele at nine to twelve months after cesarean section examined by transvaginal ultrasonography with hysterosonography.

    Time frame: Nine to twelve months after cesarean section.

  2. Ultrasonographic Measurements of Isthmocele

    Ultrasonographic characteristics of isthmocele measured by niche length, niche depth, niche width, residual myometrial thickness (RMT) and niche size (niche depth/niche depth+RMTx100\[%\]).

    Time frame: Nine to twelve months after cesarean section.

Secondary outcomes

  1. Intrauterine molecular markers of hypoxia and inflammation

    Concentrations of the following biomarkers will be assessed by analyzing an endocavitary lavage of the uterus: SDF-1/CXCL12 (an indirect marker of tissue hypoxia), G-CSF, IL-1β, IL-6, IL-10 and TNF-α (inflammatory cytokines).

    Time frame: Nine to twelve months after cesarean section.

  2. Symptoms

    Evaluation of symptoms related to CSD six months after cesarean section, measured as the presence of one or more of the following: prolonged postpartum bleeding, spotting, abnormal menstrual bleeding, dysmenorrhea, pelvic pain and/or dyspareunia.

    Time frame: Nine to twelve months after cesarean section.

  3. Risk factors

    Collection of individual data in relation to the patient characteristics and the surgical procedure to evaluate potential risk factors. Individual data: Age at inclusion, ethnicity, educational level, parity, number of cesarean deliveries, history of uterine surgery or other abdominal surgeries, body mass index, smoking status, gestational or pregestational diabetes, hypertension, other medical conditions. Surgical data: Location of the hysterotomy, need for additional hemostatic sutures, need for hemostatic material at the surgical site, requirement for antifibrinolytic or uterotonic treatment to control bleeding, estimated blood loss during the surgery.

    Time frame: Through study completion, an average of 2 years.

  4. Ultrasonographic myometrial texture patterns

    Time frame: Nine to twelve months after cesarean section.

  5. Stiffness of the uterine scar

    Stiffness differences of the uterine scar between the two groups will be compared by measuring the strain ratio (SR).

    Time frame: Nine to twelve months after cesarean section.

  6. Perinatal outcomes in following pregnancies

    Perinatal outcomes in subsequent pregnancies will be measured as the presence of one of the following: miscarriage, ectopic pregnancy, uterine rupture, placental accretism, cesarean delivery among others.

    Time frame: Through study completion, an average of 4 years.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Dec 2027, 37 months after the start.

Of 110 non-industry interventional studies with no phase under Pelvic Pain, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 37 months is above that.

Counting every sponsor, half of 114 studies reached it within 17 months; a quarter within 5 and three quarters within 30.

Primary completion moved once since we started tracking on Sep 25, 2026: Nov 2027 → Dec 2027, on Nov 3, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2024
First posted
Nov 15, 2024
StartActual
Nov 22, 2024
Primary completionEst.
Dec 2027was Nov 2027
CompletionEst.
May 2028
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 2027→Dec 2027
Nov 3, 2026
Enrollment
364→420
Nov 3, 2026
Primary outcomes
2 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameRate of IsthmoceleSix months after cesarean section. → Nine to twelve months after cesarean section.
  • Time frameUltrasonographic Measurements of IsthmoceleSix months after cesarean section. → Nine to twelve months after cesarean section.
  • DescriptionRate of Isthmocele: how it is measured was reworded
Nov 3, 2026
Secondary outcomes
4 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameIntrauterine molecular markers of hypoxia and inflammationSix months after cesarean section. → Nine to twelve months after cesarean section.
  • Time frameSymptomsSix months after cesarean section. → Nine to twelve months after cesarean section.
  • Time frameUltrasonographic myometrial texture patternsSix months after cesarean section. → Nine to twelve months after cesarean section.
  • Time frameStiffness of the uterine scarSix months after cesarean section. → Nine to twelve months after cesarean section.
  • DescriptionIntrauterine molecular markers of hypoxia and inflammation: how it is measured was reworded
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Primary completion Nov 2027→Dec 2027
    Enrollment 364→420
    Primary outcomes 2 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameRate of IsthmoceleSix months after cesarean section. → Nine to twelve months after cesarean section.
    • Time frameUltrasonographic Measurements of IsthmoceleSix months after cesarean section. → Nine to twelve months after cesarean section.
    • DescriptionRate of Isthmocele: how it is measured was reworded
    Secondary outcomes 4 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameIntrauterine molecular markers of hypoxia and inflammationSix months after cesarean section. → Nine to twelve months after cesarean section.
    • Time frameSymptomsSix months after cesarean section. → Nine to twelve months after cesarean section.
    • Time frameUltrasonographic myometrial texture patternsSix months after cesarean section. → Nine to twelve months after cesarean section.
    • Time frameStiffness of the uterine scarSix months after cesarean section. → Nine to twelve months after cesarean section.
    • DescriptionIntrauterine molecular markers of hypoxia and inflammation: how it is measured was reworded
    + 4 other changes: identifiers, verification date, design details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06691750
Responsible party
Cristina Mula Navarro (SPECIALIST IN OBSTETRIC AND GYNECOLOGY, MD, Hospital Clinic of Barcelona) — Principal investigator
First posted
Nov 15, 2024
Start date
Nov 22, 2024
Primary completion
Dec 2027 (estimated)
Completion
May 2028 (estimated)
Last update
Nov 3, 2026

Study contacts

Cristina Mula
Contact
mula@clinic.cat
+34 635486919

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion